Overview

Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)

Status:
Recruiting
Trial end date:
2024-06-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of PRA023 in participants with SSc-ILD .
Phase:
Phase 2
Details
Lead Sponsor:
Prometheus Biosciences, Inc.
Collaborator:
PPD